YouTube Facebook LinkedIn Google+ Twitter Xinginstagram rss  

The Personalized Medicine Business Model

September 25, 2013 | Personalized medicine offers tremendous potential for patients, but regulators’ demands for vast clinical studies to demonstrate the safety of new drugs, along with the need to develop the diagnostic (biomarker) tests to accompany the drug and also a clinical algorithm to guide the use of the drug/diagnostic combination, could impose huge development costs that might never be recovered by the manufacturers. Forbes
Click here to login and leave a comment.  


Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact Angela Parsons, 781.972.5467.